EA201892497A1 - Способы лечения гетеротопической оссификации - Google Patents

Способы лечения гетеротопической оссификации

Info

Publication number
EA201892497A1
EA201892497A1 EA201892497A EA201892497A EA201892497A1 EA 201892497 A1 EA201892497 A1 EA 201892497A1 EA 201892497 A EA201892497 A EA 201892497A EA 201892497 A EA201892497 A EA 201892497A EA 201892497 A1 EA201892497 A1 EA 201892497A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterotopic
assessment
treatment
methods
reduce
Prior art date
Application number
EA201892497A
Other languages
English (en)
Inventor
Кларисса Десжардинс
Донна Рой Гроган
Джеффри Нил Пэкмен
Марк Харнетт
Original Assignee
Клементиа Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Клементиа Фармасьютикалз Инк. filed Critical Клементиа Фармасьютикалз Инк.
Publication of EA201892497A1 publication Critical patent/EA201892497A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Abstract

В изобретении предлагаются схемы введения и фармацевтические составы для перорального введения паловаротена. Посредством предложенных схем введения можно уменьшить гетеротопическую оссификацию, уменьшить количество приступов и/или снизить тяжесть приступов у субъектов, страдающих прогрессирующей оссифицирующей фибродисплазией.
EA201892497A 2016-06-08 2017-06-08 Способы лечения гетеротопической оссификации EA201892497A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347381P 2016-06-08 2016-06-08
PCT/CA2017/050701 WO2017210792A1 (en) 2016-06-08 2017-06-08 Methods for treating heterotopic ossification

Publications (1)

Publication Number Publication Date
EA201892497A1 true EA201892497A1 (ru) 2019-05-31

Family

ID=60578331

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892497A EA201892497A1 (ru) 2016-06-08 2017-06-08 Способы лечения гетеротопической оссификации

Country Status (17)

Country Link
US (3) US10864194B2 (ru)
EP (2) EP4249490A3 (ru)
JP (2) JP7023868B2 (ru)
KR (1) KR102486607B1 (ru)
CN (1) CN109562099A (ru)
AU (2) AU2017276835B2 (ru)
BR (1) BR112018075422A2 (ru)
CA (1) CA3025854A1 (ru)
CL (1) CL2018003502A1 (ru)
EA (1) EA201892497A1 (ru)
ES (1) ES2963348T3 (ru)
IL (2) IL295440A (ru)
MX (2) MX2018015108A (ru)
PH (1) PH12018502563A1 (ru)
SG (1) SG11201810658PA (ru)
WO (1) WO2017210792A1 (ru)
ZA (1) ZA201808102B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2613776B1 (en) 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
EP4249490A3 (en) * 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
KR20190100187A (ko) * 2016-11-16 2019-08-28 클레멘티아 파마슈티컬즈, 인크. 다중 골연골종(mo)을 치료하는 방법
WO2020118405A1 (en) * 2018-12-13 2020-06-18 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
WO2021249240A1 (zh) * 2020-06-11 2021-12-16 养生堂有限公司 Palovarotene在抗hbv病毒治疗中的用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
ATE413375T1 (de) 2000-10-02 2008-11-15 Hoffmann La Roche Retinoide zur behandlung von emphysem
EP1430024A1 (en) 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
CN1301968C (zh) 2001-09-18 2007-02-28 霍夫曼-拉罗奇有限公司 取代的脲的类维生素a激动剂ⅱ
AUPR892501A0 (en) 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
JP2005206544A (ja) 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
WO2006101972A2 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
CN101316584A (zh) 2005-09-27 2008-12-03 北海道公立大学法人札幌医科大学 用于预防及治疗由血管通透性亢进引起的眼病的医药
JP2009527465A (ja) * 2006-01-26 2009-07-30 コンビナトアールエックス インコーポレーティッド 筋骨格障害およびそれに関連する症状の処置のための方法、組成物およびキット
KR101026652B1 (ko) 2006-03-31 2011-04-04 에프. 호프만-라 로슈 아게 레티노이드 화합물의 제조 방법
DK2026778T3 (en) 2006-05-16 2019-01-07 Io Therapeutics Llc RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
US8969350B2 (en) 2008-12-18 2015-03-03 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
WO2011011513A1 (en) * 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
EP2613776B1 (en) 2010-09-01 2020-07-29 Thomas Jefferson University Composition and method for muscle repair and regeneration
WO2012047674A2 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
US10485780B2 (en) 2011-03-14 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) * 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
KR102083041B1 (ko) 2012-02-22 2020-05-27 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 술폰아미드 화합물 및 ｔｎａｐ 억제제로서 용도
KR102092988B1 (ko) 2012-09-28 2020-03-25 벤더르빌트 유니버시티 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들
EP2918290B1 (en) 2012-11-08 2020-09-02 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
JP2016510745A (ja) 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
EP3446690A1 (en) 2013-05-22 2019-02-27 Yamaguchi University Inhibitor for retinochoroidal disorders
US20170305883A1 (en) 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
JP6589119B2 (ja) * 2015-12-24 2019-10-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ 異所性骨化を治療する方法
EP4249490A3 (en) * 2016-06-08 2023-12-13 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
IL263440A (en) 2019-01-31
US10864194B2 (en) 2020-12-15
MX2022001991A (es) 2022-03-11
SG11201810658PA (en) 2018-12-28
US20230285360A1 (en) 2023-09-14
US11622959B2 (en) 2023-04-11
JP7023868B2 (ja) 2022-02-22
AU2022202148B2 (en) 2023-08-24
IL295440A (en) 2022-10-01
CN109562099A (zh) 2019-04-02
JP2022019995A (ja) 2022-01-27
AU2022202148A1 (en) 2022-04-21
KR20190017883A (ko) 2019-02-20
KR102486607B1 (ko) 2023-01-11
PH12018502563A1 (en) 2019-10-14
AU2017276835B2 (en) 2022-03-31
EP4249490A3 (en) 2023-12-13
IL263440B (en) 2022-09-01
WO2017210792A1 (en) 2017-12-14
EP3468554A1 (en) 2019-04-17
CL2018003502A1 (es) 2019-04-26
EP3468554B1 (en) 2023-08-09
AU2017276835A1 (en) 2018-12-13
MX2018015108A (es) 2019-08-29
US20210069152A1 (en) 2021-03-11
JP2019517528A (ja) 2019-06-24
EP3468554C0 (en) 2023-08-09
EP3468554A4 (en) 2020-01-22
US20190216781A1 (en) 2019-07-18
ES2963348T3 (es) 2024-03-26
ZA201808102B (en) 2024-04-24
EP4249490A2 (en) 2023-09-27
BR112018075422A2 (pt) 2019-03-12
CA3025854A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
EA201892497A1 (ru) Способы лечения гетеротопической оссификации
CY1122581T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
NZ720949A (en) Methods and compositions for treating aging-associated conditions
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
NZ737399A (en) Ccr2 modulators
EA202090052A1 (ru) Содержащие имидазол ингибиторы alk2 киназы
DK3484502T3 (da) Blodplasmafraktioner til behandling mod aldersrelaterede kognitive forstyrrelser
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
CY1126031T1 (el) Συνθεσεις για καθαρισμο του παχεος εντερου και την αντιμετωπιση γαστρεντερικων διαταραχων
EA201791401A1 (ru) СПОСОБ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЁННОГО КИШЕЧНИКА С ПРЕОБЛАДАНИЕМ ДИАРЕИ С ПРИМЕНЕНИЕМ Bacillus coagulans SBC37-01, MTCC 5856
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MX2018015363A (es) Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
EA201791937A1 (ru) Противовоспалительные полипептиды
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы